National Survey on Hypertension (SERENITE)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00804167
First received: December 5, 2008
Last updated: July 19, 2009
Last verified: July 2009

December 5, 2008
July 19, 2009
December 2008
Not Provided
Describe the clinical characteristics of hypertensive patients aged of 75 years and older seen in general practitioner consultation according to their renal damage [ Time Frame: once ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00804167 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
National Survey on Hypertension
Profile of Hypertensive Patients Aged of 75 Years and Older Seen in General Practitioner According to Their Renal Damage.

Describe the clinical characteristics of hypertensive patients aged of 75 years and older seen in general practitioner consultation according to their renal damage

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Probability Sample

The first 3 consecutive patients seen during the GP's visit with a diagnosis of Hypertension and with renal damage

Hypertension
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
4500
July 2009
Not Provided

Inclusion Criteria:

  • Male or female aged 75 years or older
  • With a diagnosis of Hypertension treated or not, seen in general practitioner consultation
  • Who has given his/her consent to participate to the study.

Exclusion Criteria:

  • Patient who participated to a clinical trial
Both
75 Years and older
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00804167
NIS-CFR-DUM-2008/1
No
Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
AstraZeneca
Not Provided
Study Director: Alain Castaigne, Medical Director AstraZeneca
AstraZeneca
July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP